Monopar Therapeutics
MNPR
14 hedge funds and large institutions have $182K invested in Monopar Therapeutics in 2023 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
370% more capital inflows, than outflows
Capital inflows: $96.7K | Capital outflows: $20.6K
75% more funds holding
Funds holding: 8 → 14 (+6)
0.67% more ownership
Funds ownership: 1.46% → 2.13% (+0.67%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Windsor Advisory Group
Columbus,
Ohio
|
+$62.9K |
| 2 |
Two Sigma Securities
New York
|
+$17.2K |
| 3 |
HRT Financial
New York
|
+$9.14K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.31K |
| 5 |
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$56 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$9.6K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.09K |
| 3 |
Morgan Stanley
New York
|
-$2.24K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$482 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$128 |
MNPR Hedge Fund Activity: Q3 2023 in Review
14 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2023, worth a combined $182K — up 11% from $165K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new MNPR positions and 1 closed out — a net gain of 6 holders — while 0 added to existing stakes and 5 trimmed.
The largest buyer was Windsor Advisory Group, opening a new position worth an estimated $62.9K. The largest seller was Millennium Management, cutting an estimated $9.6K.
- 14 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2023, up from 8 in Q2 2023.
- Funds reported $182K of Monopar Therapeutics stock for Q3 2023, up 11% quarter-over-quarter.
- 7 funds opened new Monopar Therapeutics positions in Q3 2023 and 1 closed out, a net change of +6 holders.
- The largest Monopar Therapeutics buyer in Q3 2023 was Windsor Advisory Group, an estimated $62.9K added.
- The largest Monopar Therapeutics seller in Q3 2023 was Millennium Management, an estimated $9.6K sold.
Based on aggregated 13F filings for Q3 2023.